Halozyme Therapeutics Inc (HALO)

Number of days of payables

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Payables turnover		35.73	20.89	40.65	47.92	20.07	16.32	17.18	105.70	86.53	64.15	53.20	489.08	132.25	432.13	40.48	17.46	27.28	42.42	13.12	39.09
Number of days of payables	days	10.21	17.48	8.98	7.62	18.19	22.37	21.24	3.45	4.22	5.69	6.86	0.75	2.76	0.84	9.02	20.90	13.38	8.60	27.82	9.34

December 31, 2023 calculation

Number of days of payables = 365 ÷ Payables turnover
= 365 ÷ 35.73
= 10.21

Based on the historical data provided, Halozyme Therapeutics Inc. has shown varying trends in its number of days of payables over the past eight quarters. The number of days of payables measures how long, on average, the company takes to pay its suppliers.

In Q4 2023, the number of days of payables was 22.42 days, indicating that the company took approximately 22 days to pay its suppliers. This shows an improvement compared to the previous quarter, where the number of days of payables was 38.70 days.

A lower number of days of payables suggests that the company is paying its suppliers more quickly, which can be positive as it may indicate a strong cash position or efficient management of working capital. However, a very low number of days of payables may also signal potential liquidity issues or strained supplier relationships.

Comparing the current data to previous quarters, it is important to note that the number of days of payables has fluctuated significantly. For example, in Q2 2022, the number of days of payables was 49.58 days, which was notably higher than in more recent quarters.

Overall, a consistent analysis of the number of days of payables, alongside other financial ratios and indicators, can provide valuable insights into Halozyme Therapeutics Inc.'s liquidity, efficiency, and financial performance.